オプションチェーンは、Amneal Pharmaceuticalsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Amneal Pharmaceuticalsの市場センチメントを評価します。.

Amneal Pharmaceuticals (NASDAQ:AMRX) 株価情報, オプションチェーン

Amneal Pharmaceuticals

Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals Inc

Here's the major earnings before the open tomorrow

Amneal Pharmaceuticals Non-GAAP EPS of $0.16 beats by $0.02, revenue of $702.5M beats by $8.77M

Bargain Priced Viatris Reports Strong Q3 Earnings Results

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript

Amneal Pharma ( ($AMRX) ) has released its Q3 earnings. Here is a breakdown of the information Amneal Pharma presented to its investors. Amneal Pha...

Amneal Pharmaceuticals Reports Q3 2024 Financial Results

Barclays analyst Balaji Prasad maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report) today and set a price target of $10.00. T...

Barclays Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)

High quality 'SMID-cap' stocks with cyclical exposure – MS

In a report released today, Les Sulewski from Truist Financial reiterated a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report). The comp...

Truist Financial Keeps Their Buy Rating on Amneal Pharmaceuticals (AMRX)

Amneal Pharmaceuticals (AMRX) announced the advancement of two key strategic initiatives. First, the Company has resubmitted to the U.S. Food and D...

Amneal resubmits DHE autoinjector NDA, gets FDA approval for exenatide

Amneal gets FDA approval for generic Byetta, resubmits DHE NDA

ADNT

AGIO

AMCX

AMRX

ANIP

AROC

ASAN

ASGN

ATSG

BEPC

BLMN

CARG

CBWTF

CEIX

CPRI

CRLBF

DBRG

DCBO

FLGT

GBTG

GLNG

HUMA

HWKN

IBRX

ICAGY

IFRX

ILLMF

IOVA

LAMR

LBRT

OCGN

OSCR

PAGP

PARAA

QDEL

QTRHF

RCMT

SDRL

SKYW

SONY

SPTM

STRL

TBBK

TCBI

TEVA

TGLS

TGNA

UMBF

USLM

VTRS

WERN

XERS

Press Releases

Amneal Reports Second Quarter 2024 Financial Results

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

Amneal to Report Third Quarter 2024 Results on November 8, 2024

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

Amneal Reports Third Quarter 2024 Financial Results

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

NTRB

NTRBW

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Arvinas

Axsome Therapeutics

Belite Bio, Inc - American Depositary Shares

Belite Bio

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences

Harrow

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Longboard Pharmaceuticals, Inc. - Common Stock

Longboard Pharmaceuticals

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Ocular Therapeutix

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Verona Pharma plc - American Depositary Shares

Verona Pharma

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

Piper Sandler

Truist Securities

JP Morgan

Barclays

Goldman Sachs

Comments

Amneal Pharmaceuticals

Amneal Pharmaceuticals (AMRX) オプション

Amneal Pharmaceuticals (NASDAQ:AMRX) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル